Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGDS | O60760 | 6/20 | 1.00 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | KLKB1 | P03952 | 4/20 | 0.37 |
| ▸ | CTSD | P07339 | 1/20 | 0.36 |
| ▸ | GUSB | P08236 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | F2 | P00734 | 3/20 | 0.36 |
| ▸ | F10 | P00742 | 1/20 | 0.36 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3220415 | 0.91 | HPGDS (0.83) | HPGDSGLARAB9AL3MBTL1NPSR1 | |
| SCHEMBL12083884 | 0.91 | HPGDS (0.82) | HPGDSRAB9AGRM4 | |
| SCHEMBL12083908 | 0.89 | HPGDS (0.81) | HPGDSGLARAB9AL3MBTL1NPSR1 | |
| SCHEMBL12084139 | 0.89 | HPGDS (0.81) | HPGDSGLARAB9AL3MBTL1NPSR1 | |
| SCHEMBL12084042 | 0.89 | HPGDS (0.81) | HPGDSGLARAB9AL3MBTL1NPSR1 | |
| SCHEMBL3228149 | 0.89 | HPGDS (0.81) | HPGDSGLAL3MBTL1MEN1KMT2A | |
| SCHEMBL12084132 | 0.88 | HPGDS (0.79) | HPGDSGLAMEN1KMT2AF2 | |
| SCHEMBL14313336 | 0.88 | HPGDS (0.78) | HPGDSGLARAB9AL3MBTL1NPSR1 | |
| SCHEMBL12083696 | 0.88 | HPGDS (0.78) | HPGDSGLARAB9AL3MBTL1NPSR1 | |
| SCHEMBL3219598 | 0.87 | HPGDS (0.77) | HPGDSGLARAB9AL3MBTL1NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2370077-A2 | METHOD FOR TREATING MACULAR DEGENERATION | SANOFI (FR) | 2011-10-05 | — | — | EP | claimed |
| EP-2653193-A1 | Method for treating macular degeneration | SANOFI (FR) | 2013-10-23 | — | — | EP | disclosed |
| EP-2142516-B1 | PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS | SANOFI SA (FR) | 2012-12-26 | — | — | EP | disclosed |
| US-8258130-B2 | Pyrimidine hydrazide compounds as PGDS inhibitors | SANOFI (FR) | 2012-09-04 | — | — | US | disclosed |
| US-8258130-B2 | Pyrimidine hydrazide compounds as PGDS inhibitors | SANOFI (FR) | 2012-09-04 | — | — | US | disclosed |
| EP-2370077-A2 | METHOD FOR TREATING MACULAR DEGENERATION | SANOFI (FR) | 2011-10-05 | — | — | EP | disclosed |
| WO-2010080563-A2 | METHOD FOR TREATING MACULAR DEGENERATION | SANOFI-AVENTIS (FR) | 2010-07-15 | — | — | WO | disclosed |
| US-20100048568-A1 | PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS | SANOFI-AVENTIS (FR) | 2010-02-25 | — | — | US | disclosed |
| US-20100048568-A1 | PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS | SANOFI-AVENTIS (FR) | 2010-02-25 | — | — | US | disclosed |
| WO-2008121670-A1 | PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS | SANOFI-AVENTIS (FR) | 2008-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048568-A1 | PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS | HRH2, HRH1, HRH4 | HPGDS 10/4885GLA 1529/4885RAB9A 2033/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.